KAISA HEALTH GROUP HOLDINGS LIMITED (HKEX: 00876) has issued a circular dated 13 August 2026 proposing to change its English name from “Kaisa Health Group Holdings Limited” to “Qinghai Biotech Pharmaceutical Group Limited” and adopt “青海生物製藥集團有限公司” as its new Chinese secondary name.
Key drivers • Strategic realignment: Management states the new identity will better reflect the Group’s positioning following its planned acquisition of an interest in Qinghai Pharmaceutical Co. Ltd., a healthcare enterprise with more than 60 years of operating history (announcement dated 18 March 2026). • Branding benefits: The Board believes the rebranding will support ongoing business expansion and enhance market recognition.
Approval pathway 1. Special Resolution: Shareholders will vote on the name change at a Special General Meeting (SGM) scheduled for 11:00 a.m. on Tuesday, 1 September 2026, at Conference Room Cambridge Lab, 19/F, Office Plus @ Sheung Wan, Hong Kong. 2. Regulatory Clearance: Final effectiveness hinges on the Registrar of Companies in Bermuda issuing the Certificate of Change of Name and Certificate of Secondary Name.
Implementation and impact • Trading and certificates: Existing share certificates bearing “Kaisa Health Group Holdings Limited” will remain valid for trading, settlement and registration; no free exchange of certificates is planned. • Stock short names and logo: Subject to Hong Kong Stock Exchange confirmation, new English and Chinese stock short names and a refreshed corporate logo will be adopted after the change takes effect. • Shareholder rights and operations: The proposal will not affect shareholder rights, trading of shares, or day-to-day operations and financial position.
Meeting logistics • Record date: Tuesday, 1 September 2026. • Register closure: 27 August–1 September 2026 (both dates inclusive). Share transfers for voting eligibility must be lodged by 4:30 p.m. on 26 August 2026. • Proxy arrangements: A new proxy form is enclosed; previously distributed forms are invalid.
Recommendation The Board unanimously supports the resolution and urges shareholders to vote in favour, citing alignment with the Group’s post-acquisition strategic direction.